AngioDynamics has received Food and Drug Administration 510(k) clearance for its Morpheus CT peripherally inserted central catheter (PICC).
Morpheus is constructed of Durathane, a biocompatible and durable material that offers increased stiffness on the proximal end for ease of placement, a softer distal end for patient comfort, and simplified site care, according to the Queensbury, NY-based company, a majority-owned subsidiary of E-Z-EM.
Indicated for use with CT injectors, Morpheus will allow physicians to utilize the existing PICC for both medications and CT imaging, avoiding the need for an additional access site, according to the vendor. AngioDynamics expects to begin marketing Morpheus in the U.S. in September.
By AuntMinnie.com staff writersJuly 29, 2004
Related Reading
E-Z-EM shifts barium manufacturing, June 9, 2004
AngioDynamics prices IPO, May 28, 2004
AngioDynamics unveils Morpheus, April 15, 2004
E-Z-EM turns in record Q3, April 8, 2004
E-Z-EM sponsors VC CME, March 11, 2004
Copyright © 2004 AuntMinnie.com
